Bacterial inhibition efficiency of prilocaine and bupivacaine

Basit Öğe Kaydı
dc.contributor.authorKesici, Sevgi
dc.contributor.authorDemirci, Mehmet
dc.contributor.authorKesici, Ugur
dc.date.accessioned2024-03-13T10:32:55Z
dc.date.available2024-03-13T10:32:55Z
dc.date.issued2019
dc.departmentİstanbul Beykent Üniversitesien_US
dc.description.abstractThis study aimed to demonstrate the antibacterial effects of bupivacaine and prilocaine on Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. In our study, the in vitro antimicrobial effects of 20 mg/mL prilocaine and 5 mg/mL bupivacaine were tested against a S. aureus American-type culture collection (ATCC) 29213, P. aeruginosa ATCC 27853, and E. coli ATCC 25922, divided into Group P (Prilocaine) and Group B (Bupivacaine), respectively. S. aureus ATCC 29213, P. aeruginosa ATCC 27853, and E. coli ATCC 25922 were cultured on Mueller Hinton agar (Oxoid, Basingstoke, UK) plates for 18 to 24 hours at 37 degrees C. In terms of inhibition zone diameters, inhibition of S. aureus ATCC 29213 was observed in both groups at the 12th and 24th hours. The 12th- and 24th-hour S. aureus ATCC 29213 value was significantly higher in Group P compared with Group B (P = .008). At the 12th and 24th hours, inhibition of E. coli ATCC 25922 was observed in both groups. The 12th- and 24th-hour E. coli ATCC 25922 value was significantly higher in Group P compared with Group B (P = .008). In our study, it was seen that prilocaine and bupivacaine had an antimicrobial effect on S. aureus and E. coli. In the comparison between these two local anesthetics (LAs), this effect was found to be significantly higher in prilocaine than bupivacaine. Therefore, we are of the opinion that antimicrobial effect potentials should also be taken into account in the selection of an LA agent in order to prevent the complications of an infection that might develop during LA infiltration and might lead to serious morbidity.en_US
dc.identifier.doi10.1111/iwj.13180
dc.identifier.endpage1189en_US
dc.identifier.issn1742-4801
dc.identifier.issn1742-481X
dc.identifier.issue5en_US
dc.identifier.pmid31407480en_US
dc.identifier.scopus2-s2.0-85070708143en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1185en_US
dc.identifier.urihttps://doi.org/10.1111/iwj.13180
dc.identifier.urihttps://hdl.handle.net/20.500.12662/3661
dc.identifier.volume16en_US
dc.identifier.wosWOS:000480639100001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Wound Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectantibacterialen_US
dc.subjectwound healingen_US
dc.subjectprilocaineen_US
dc.subjectbupivacaineen_US
dc.subjectStaphylococcus aureusen_US
dc.titleBacterial inhibition efficiency of prilocaine and bupivacaineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu